Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.54 |
| ▸ | AMY1A | P0DUB6 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.48 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL723743 | 0.99 | KDM1A (0.58) | KDM1AHDAC3HDAC1HDAC7HDAC8 | |
| SCHEMBL723275 | 0.90 | HDAC3 (0.55) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL722657 | 0.89 | HDAC3 (0.54) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL721855 | 0.89 | HDAC3 (0.54) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL721918 | 0.89 | HPGDS (0.54) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL721844 | 0.88 | HDAC3 (0.53) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| Hydrochloric Acid SCHEMBL771834 | 0.88 | HPGDS (0.53) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL30621782 | 0.81 | EGFR (0.68) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL723031 | 0.81 | EGFR (0.68) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL15151704 | 0.77 | AMY1A (0.52) | KDM1AAMY1AALDH1A1ALOX5TRPC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3793548-A1 | COMPOUNDS FOR TREATMENT OF PANCREATIC CANCER | University of Tennessee Research Foundation (US) | 2021-03-24 | — | — | EP | claimed |
| EP-3793549-A1 | COMPOUNDS FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER AND OVARIAN CANCER | University of Tennessee Research Foundation (US) | 2021-03-24 | — | — | EP | claimed |
| WO-2021041744-A1 | RYL BENZOYL IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF LUNG CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-03-04 | — | — | WO | claimed |
| EP-2608671-B1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX INC (US) | 2018-12-12 | — | — | EP | claimed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | claimed |
| WO-2012027481-A9 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2013-10-10 | — | — | WO | claimed |
| EP-2608671-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Gtx, Inc. (US) | 2013-07-03 | — | — | EP | claimed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | claimed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | claimed |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-11465987-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| EP-2608671-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Gtx, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | KDM1A 2331/4885HDAC3 39/4885HDAC1 19/4885 |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | KDM1A 2331/4885HDAC3 39/4885HDAC1 19/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | KDM1A 2331/4885HDAC3 39/4885HDAC1 19/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | KDM1A 2331/4885HDAC3 39/4885HDAC1 19/4885 |
| US-11465987-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | KDM1A 2331/4885HDAC3 39/4885HDAC1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.